Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review
Abstract Current therapies for Parkinson’s disease (PD) are palliative, of which the levodopa/carbidopa therapy remains the primary choice but is unable to modulate the progression of neurodegeneration. Due to the complication of such a multifactorial disorder and significant limitations of the ther...
Main Authors: | Tapan Behl, Gagandeep Kaur, Ovidiu Fratila, Camelia Buhas, Claudia Teodora Judea-Pusta, Nicoleta Negrut, Cristiana Bustea, Simona Bungau |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Translational Neurodegeneration |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40035-020-00226-x |
Similar Items
-
Impact of Gba2 on neuronopathic Gaucher’s disease and α-synuclein accumulation in medaka (Oryzias latipes)
by: Etsuro Nakanishi, et al.
Published: (2021-05-01) -
D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model
by: Donghoon Kim, et al.
Published: (2018-04-01) -
Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers
by: Eileen E. Moran, et al.
Published: (2021-02-01) -
Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation
by: Shi-yu Yang, et al.
Published: (2020-02-01) -
Glucocerebrosidase and its relevance to Parkinson disease
by: Jenny Do, et al.
Published: (2019-08-01)